Anergen, Inc.

Redwood City, CA 94063

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $0.0
First Award Date 09/22/98
Most Recent Award Date 09/30/98

Key Personnel

Last Name Name Awards Contact
Howard Maureen Howard 2
Deshpande Shrikant V Deshpande 1

3 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 09/30/99

DESCRIPTION (Adapted from Applicant's Abstract): Myestheria gravis (MG) is an antibody-mediated, T-cell-dependent autoimmune disease caused by reduction in the number of acetylcholine receptors (AChR) at the neuromuscular junction. It is one of the best characterized autoimmune diseases, with well def...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 09/30/99

DESCRIPTION: (Adapted from the applicant's abstract) Anergen Inc. has recently demonstrated in a Phase IIa clinical trial in rheumatoid arthritis preliminary validation of a generic concept that MHC analog peptides can be used to vaccinate against MHC-linked autoimmune diseases (1). Using this same c...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/22/98 - 08/31/99

DESCRIPTION: (Adapted from the applicant's abstract) Type I diabetes is caused by selective destruction of the insulin-producing islet cells in the pancreas. This destruction is mediated by autoreactive T cells and correlates with the migration of a sub-population of IFN gamma-producing cells to the site of ti...